share_log

Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target

Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target

奧本海默將Avalo Therapeutics上調至跑贏大盤,宣佈目標股價爲35美元
Moomoo 24/7 ·  04/16 08:52

Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:AVTX) from Perform to Outperform and announces $35 price target.

奧本海默分析師利蘭·格歇爾將Avalo Therapeutics(納斯達克股票代碼:AVTX)從表現上調至跑贏大盤,並宣佈了35美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論